Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2017-09-18 Interim / Quarterly Rep…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
PR in English
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive report detailing Innate Pharma's financial results for the first half of 2017. It includes consolidated financial statements, balance sheets, income statements, and detailed management commentary on clinical pipeline progress. It is not a mere announcement (RPA) because it contains substantive financial data and analysis for the interim period. Therefore, it is classified as an Interim/Quarterly Report. H1 2017
2017-09-18 English
CP en français
Regulatory Filings Classification · 95% confidence The document is titled with a date and location ("Marseille, le 11 septembre 2017, 7h00 CEST") and begins by announcing the presentation of new preclinical data at a specific international conference (CRI-CIMT-EATI-AACR 2017). It details scientific findings regarding two compounds (IPH5401 and monalizumab) and includes quotes from management and extensive 'About' sections for the company and its pipeline assets. This structure is characteristic of a press release issued to disseminate important, timely scientific or operational updates to the market and investors, often coinciding with a conference presentation. Since it is an announcement of scientific data presented at a conference, and not a formal regulatory filing like a 10-K, a transcript of a call, or a formal dividend notice, the most appropriate classification is 'Earnings Release' (ER) if it were quarterly results, but since it is scientific/pipeline news, it fits best under the general 'Regulatory Filings' (RNS) as a broad announcement category, or potentially 'Investor Presentation' (IP) if it were the presentation itself. Given the format is a press release announcing data presented elsewhere, RNS is the safest general regulatory announcement category, although 'ER' is often used broadly for results announcements. However, since the content is purely scientific data presentation at a conference, and not financial results, 'RNS' (Regulatory Filings/General Announcement) is the best fit among the provided options for a non-standard, time-sensitive corporate announcement.
2017-09-11 French
PR in English
Regulatory Filings Classification · 95% confidence The document is a press release dated September 11, 2017, announcing that new preclinical data for IPH5401 and monalizumab were presented at the International Cancer Immunotherapy conference (CRI-CIMT-EATI-AACR 2017). It details the scientific findings from posters presented at the conference and includes quotes from management regarding the implications for ongoing and future clinical trials. This type of announcement, focusing on scientific data presentation at an industry conference, is characteristic of an Investor Presentation (IP) or a general scientific update, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a formal report (AR/IR). Since it is a detailed presentation of scientific rationale and data supporting product development, 'Investor Presentation' (IP) is the most fitting category, as these often include detailed scientific slides or summaries presented at investor/scientific events.
2017-09-11 English
CP en français
Share Issue/Capital Change Classification · 98% confidence The document is titled 'NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 4 AOUT 2017' (New number of shares and voting rights as of August 4, 2017). It explicitly cites French regulatory articles (Code de Commerce and AMF regulations) requiring the publication of the total number of shares and voting rights. This content directly relates to the capital structure and shareholder rights reporting, specifically concerning the total share count used for calculating voting thresholds. This aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes and related voting rights disclosures, even if it's a routine update rather than a post-meeting result.
2017-08-08 French
PR in English
Share Issue/Capital Change Classification · 95% confidence The document explicitly states its purpose in the title: "NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT AUGUST 4, 2017". It provides the total number of shares outstanding and the theoretical/exercisable voting rights, citing compliance with French regulatory articles (L. 233-8 II of the French « Code de Commerce » and article 223-16 of the AMF charter). This type of mandatory disclosure regarding share capital structure and voting rights is a specific regulatory announcement. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). While it relates to share capital, it is a mandatory disclosure of the current count, not a transaction (POS) or a general capital change announcement (SHA). It most closely aligns with a specific regulatory filing or announcement that doesn't fit the other precise categories. Given the nature of mandatory disclosure of shareholding thresholds and voting rights under AMF rules, it is best classified as a general Regulatory Filing (RNS), as it is a specific, periodic regulatory update that isn't covered by the other codes like DIRS (Director's Dealing) or MRQ (Major Shareholding Notification, which usually reports a *change* crossing a threshold, not the static count as of a specific date). Since RNS is the fallback for miscellaneous regulatory announcements, it is the most appropriate fit.
2017-08-08 English
PR in English
Share Issue/Capital Change Classification · 99% confidence The document details the finalization of a contribution in kind agreement where Innate Pharma issues 3,343,748 ordinary shares to Novo Nordisk A/S in consideration for acquiring rights to an anti-C5aR antibody. This transaction involves a significant increase in Novo Nordisk A/S's stake in Innate Pharma's share capital (from 10.3% to 15.5%) through the issuance of new shares. This action directly relates to changes in the company's capital structure and financing activities, specifically through the issuance of shares as consideration for an asset contribution. This aligns best with the 'Capital/Financing Update' category (CAP). It is not an earnings release (ER), an annual report (10-K), or a general management report (MDA), but a specific corporate action involving share issuance for an acquisition.
2017-07-13 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.